Screener
Crinetics Pharmaceuticals CRNX Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredCompensationPlanAssets.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Prepaid clinical costs | $21,439 | $19,547 |
| Interest receivable | 8,957 | 7,758 |
| Deferred compensation plan | 4,897 | 3,249 |
| Prepaid research and development costs | 2,626 | 2,901 |
| Loyal preferred stock (see Note 7) | 2,000 | 2,000 |
| Prepaid subscriptions | 838 | 1,255 |
| Other | 6,426 | 3,456 |
| Total prepaid expenses and other assets | 47,183 | 40,166 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's other non-current assets?
- Crinetics Pharmaceuticals (CRNX) reported other non-current assets of $4.9M in Q1 2026.
- How has Crinetics Pharmaceuticals's other non-current assets changed year-over-year?
- Crinetics Pharmaceuticals's other non-current assets decreased by 65.4% year-over-year, from $14.15M to $4.9M.
- What is the long-term trend for Crinetics Pharmaceuticals's other non-current assets?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's other non-current assets has grown at a 141.0% compound annual growth rate (CAGR), from $40K to $3.25M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about Crinetics Pharmaceuticals's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude